Vermillion Gets Permits to Open Clinical Reference Laboratory | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion said today that it has obtained permits and completed regulatory processes required for opening a clinical reference laboratory.

In a filing with the US Securities and Exchange Commission, the company said that the lab, Aspira Labs, "will offer tests related to gynecologic oncology and women’s health," including its OVA1 ovarian cancer test.

The lab will be led by Herbert Fritsche, formerly clinical chemistry section chief in the Department of Pathology and Laboratory Medicine at MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."